Barclays PLC raised its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPS – Free Report) by 21.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 413,066 shares of the company’s stock after purchasing an additional 72,448 shares during the quarter. Barclays PLC’s holdings in COMPASS Pathways were worth $3,420,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Oppenheimer & Co. Inc. bought a new stake in shares of COMPASS Pathways during the second quarter worth $86,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of COMPASS Pathways by 3.2% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 398,335 shares of the company’s stock worth $3,298,000 after purchasing an additional 12,414 shares during the last quarter. TAP Consulting LLC bought a new stake in shares of COMPASS Pathways during the second quarter worth $93,000. Putnam Investments LLC lifted its position in shares of COMPASS Pathways by 41.9% during the first quarter. Putnam Investments LLC now owns 243,863 shares of the company’s stock worth $2,422,000 after purchasing an additional 71,964 shares during the last quarter. Finally, State Street Corp increased its stake in shares of COMPASS Pathways by 534.2% during the first quarter. State Street Corp now owns 104,506 shares of the company’s stock valued at $1,038,000 after buying an additional 88,028 shares during the period. 18.13% of the stock is currently owned by institutional investors.
COMPASS Pathways Price Performance
CMPS opened at $5.27 on Monday. The business’s 50-day moving average is $7.11 and its two-hundred day moving average is $7.98. COMPASS Pathways plc has a 1 year low of $5.22 and a 1 year high of $11.48. The company has a debt-to-equity ratio of 0.12, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market capitalization of $241.16 million, a PE ratio of -2.03 and a beta of 2.56.
Wall Street Analysts Forecast Growth
COMPASS Pathways Company Profile
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
- Five stocks we like better than COMPASS Pathways
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 11/6 – 11/10
- Retail Stocks Investing, Explained
- Data giants MongoDB and Snowflake just got upgraded
- Technology Stocks Explained: Here’s What to Know About Tech
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.